Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand

Industry watchers have long been speculating on how would take on heavyweights and when it priced its new hep C regimen. And now, they have their answer: Undercut them. Big-time.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS